Radiation oncology journal最新文献

{"title":"Pulsed low-dose rate radiotherapy for recurrent bone sarcomas: case reports and brief review","authors":"Ru Xin Wong, Zubin Master, Eric Pang, Valerie Yang, W. S. Looi","doi":"10.3857/roj.2023.00815","DOIUrl":"https://doi.org/10.3857/roj.2023.00815","url":null,"abstract":"","PeriodicalId":94184,"journal":{"name":"Radiation oncology journal","volume":"67 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139841032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison between 1-week and 2-week palliative radiotherapy courses for superior vena cava syndrome.","authors":"Jongmoo Park,&nbsp;Jeong Eun Lee","doi":"10.3857/roj.2023.00626","DOIUrl":"10.3857/roj.2023.00626","url":null,"abstract":"<p><strong>Purpose: </strong>The aim of this study was to evaluate the effectiveness of palliative radiation therapy (RT) for superior vena cava (SVC) syndrome from lung cancer and to compare the 2-week and 1-week schedules.</p><p><strong>Materials and methods: </strong>A retrospective study was conducted on lung cancer patients with palliative RT for SVC syndrome. Patients received 30 Gy in 10 fractions (2-week group) or 20 Gy in 5 fractions (1-week group) between July 2012 and June 2022. Treatment outcomes were evaluated at 1 to 2 months after RT. The tumor response and recanalization were evaluated based on the computed tomography (CT).</p><p><strong>Results: </strong>Of the 39 patients, 24 received a 2-week course RT and 15 received a 1-week course of RT. The most common SVC-associated symptoms were edema (51.3%) and dyspnea (43.6%). There were no significant differences in performance status, histology, and grade of SVC. Symptom relief in symptomatic patients was comparable (85.7% in the 2-week group vs. 91.6% in the 1-week group; p = 0.581). There were no significant differences between the 2-week and 1-week groups in recanalization rates (62.5% vs. 60.0%; p = 0.876), tumor responses (75% vs. 60.0%; p = 0.876), and 6-month overall survival rates (29.2% vs. 36.4%; p = 0.726). In each of the two groups, one patient was consulted for re-irradiation. The median survival were 3.7 months for the 2-week group and 4.4 months for the 1-week group.</p><p><strong>Conclusion: </strong>In patients with SVC syndrome, the palliative effect of a 1-week course was equivalent to that of a 2-week course. Given the poor prognosis, a 1-week course may be an option.</p>","PeriodicalId":94184,"journal":{"name":"Radiation oncology journal","volume":"41 3","pages":"178-185"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cf/2d/roj-2023-00626.PMC10556839.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41176047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical outcomes of radical radiotherapy for pulmonary sarcomatoid carcinoma.","authors":"Choong-Won Lee,&nbsp;Byoung Hyuck Kim,&nbsp;Hak Jae Kim","doi":"10.3857/roj.2023.00437","DOIUrl":"10.3857/roj.2023.00437","url":null,"abstract":"<p><strong>Purpose: </strong>Pulmonary sarcomatoid carcinoma (PSC) is recognized for its aggressiveness and poor prognosis. The role of radical radiotherapy in PSC remains uncertain due to its scarcity and limited data. In the absence of an effective systemic agent, this study aims to explore the possibility of cure and to investigate potential prognostic factors and treatment outcomes.</p><p><strong>Materials and methods: </strong>From January 2005 to December 2021, 149 PSC patients were identified. Among 62 patients who received radiotherapy for lung lesions, 25 who underwent palliative radiotherapy and 16 who underwent surgery were excluded.</p><p><strong>Results: </strong>The median patient age was 71 years. The majority were male, and 17 patients (81.0%) were diagnosed at an advanced stage. After radical radiotherapy, distant metastasis (47.6%) was the most common site of failure, while the local recurrence rate was quite low (9.5%). Eventually, five patients (26.3%) demonstrated either a partial response or complete remission, including three complete remissions with durable responses. The median progression-free survival (PFS) and overall survival were 4.6 months and 7.9 months, respectively. Univariate and multivariate analyses revealed that a tumor size >5 cm was associated with a worse prognosis (p = 0.045), while a radiation dose >58 GyEQD2 was significantly associated with better PFS (p = 0.038).</p><p><strong>Conclusion: </strong>This study demonstrates clinical outcomes after radical radiotherapy in managing PSC, suggesting tumor size and radiation dose could be a predictor of a systemic response. Given the known bad prognosis but complete remission could be achieved in certain subgroups, future research should explore the potential strategies using radical radiotherapy for this challenging patient population.</p>","PeriodicalId":94184,"journal":{"name":"Radiation oncology journal","volume":"41 3","pages":"163-171"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fd/bc/roj-2023-00437.PMC10556836.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41161744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility of artificial intelligence-driven interfractional monitoring of organ changes by mega-voltage computed tomography in intensity-modulated radiotherapy of prostate cancer.","authors":"Yohan Lee,&nbsp;Hyun Joon Choi,&nbsp;Hyemi Kim,&nbsp;Sunghyun Kim,&nbsp;Mi Sun Kim,&nbsp;Hyejung Cha,&nbsp;Young Ju Eum,&nbsp;Hyosung Cho,&nbsp;Jeong Eun Park,&nbsp;Sei Hwan You","doi":"10.3857/roj.2023.00444","DOIUrl":"https://doi.org/10.3857/roj.2023.00444","url":null,"abstract":"<p><strong>Purpose: </strong>High-dose radiotherapy (RT) for localized prostate cancer requires careful consideration of target position changes and adjacent organs-at-risk (OARs), such as the rectum and bladder. Therefore, daily monitoring of target position and OAR changes is crucial in minimizing interfractional dosimetric uncertainties. For efficient monitoring of the internal condition of patients, we assessed the feasibility of an auto-segmentation of OARs on the daily acquired images, such as megavoltage computed tomography (MVCT), via a commercial artificial intelligence (AI)-based solution in this study.</p><p><strong>Materials and methods: </strong>We collected MVCT images weekly during the entire course of RT for 100 prostate cancer patients treated with the helical TomoTherapy system. Based on the manually contoured body outline, the bladder including prostate area, and rectal balloon regions for the 100 MVCT images, we trained the commercially available fully convolutional (FC)-DenseNet model and tested its auto-contouring performance.</p><p><strong>Results: </strong>Based on the optimally determined hyperparameters, the FC-DenseNet model successfully auto-contoured all regions of interest showing high dice similarity coefficient (DSC) over 0.8 and a small mean surface distance (MSD) within 1.43 mm in reference to the manually contoured data. With this well-trained AI model, we have efficiently monitored the patient's internal condition through six MVCT scans, analyzing DSC, MSD, centroid, and volume differences.</p><p><strong>Conclusion: </strong>We have verified the feasibility of utilizing a commercial AI-based model for auto-segmentation with low-quality daily MVCT images. In the future, we will establish a fast and accurate auto-segmentation and internal organ monitoring system for efficiently determining the time for adaptive replanning.</p>","PeriodicalId":94184,"journal":{"name":"Radiation oncology journal","volume":"41 3","pages":"186-198"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/10/5e/roj-2023-00444.PMC10556843.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41161778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Has the growing evidence of radiotherapy for hepatocellular carcinoma increased the use of radiotherapy in elderly patients?","authors":"Tae Hyun Kim","doi":"10.3857/roj.2023.00710","DOIUrl":"https://doi.org/10.3857/roj.2023.00710","url":null,"abstract":"Primary liver cancer, mostly hepatocellular carcinoma (HCC), is the sixth most common cancer and the third leading cause of cancer-related deaths worldwide [1]. HCC develops mostly in patients with chronic liver disease, such as cirrhosis from hepatitis B and C virus infection, alcoholic abuse","PeriodicalId":94184,"journal":{"name":"Radiation oncology journal","volume":"41 3","pages":"141-143"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/75/9f/roj-2023-00710.PMC10556838.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41171430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bleeding metastasis of renal cell cancer to anal canal treated with radiation.","authors":"Cemal Ulusoy,&nbsp;Sila Guclu Mete,&nbsp;Andrej Nikolovski","doi":"10.3857/roj.2023.00465","DOIUrl":"10.3857/roj.2023.00465","url":null,"abstract":"<p><p>Renal cell cancer (RCC) has the ability to metastasize to various organs, including the anal canal which is reported to be the rarest location. An 88-year-old male patient who had previously been treated for right RCC subsequently developed distant metastases to the prostate, lungs, and small bowel. Four years following nephrectomy, the patient presented with a bleeding anal mass which was excised and has been proven to be an anal canal metastasis of RCC. Eight months post excision, regrowth occurred. The patient underwent stereotactic ablative body radiotherapy resulting in satisfactory regression during the 2-month follow-up period, without episodes of bleeding. The treatment options for metastatic post-nephrectomy disease should be considered with a multidisciplinary approach in order to achieve satisfactory symptom relief.</p>","PeriodicalId":94184,"journal":{"name":"Radiation oncology journal","volume":"41 3","pages":"217-221"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/61/6c/roj-2023-00465.PMC10556841.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41143833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Developing prompts from large language model for extracting clinical information from pathology and ultrasound reports in breast cancer.","authors":"Hyeon Seok Choi,&nbsp;Jun Yeong Song,&nbsp;Kyung Hwan Shin,&nbsp;Ji Hyun Chang,&nbsp;Bum-Sup Jang","doi":"10.3857/roj.2023.00633","DOIUrl":"10.3857/roj.2023.00633","url":null,"abstract":"<p><strong>Purpose: </strong>We aimed to evaluate the time and cost of developing prompts using large language model (LLM), tailored to extract clinical factors in breast cancer patients and their accuracy.</p><p><strong>Materials and methods: </strong>We collected data from reports of surgical pathology and ultrasound from breast cancer patients who underwent radiotherapy from 2020 to 2022. We extracted the information using the Generative Pre-trained Transformer (GPT) for Sheets and Docs extension plugin and termed this the \"LLM\" method. The time and cost of developing the prompts with LLM methods were assessed and compared with those spent on collecting information with \"full manual\" and \"LLM-assisted manual\" methods. To assess accuracy, 340 patients were randomly selected, and the extracted information by LLM method were compared with those collected by \"full manual\" method.</p><p><strong>Results: </strong>Data from 2,931 patients were collected. We developed 12 prompts for Extract function and 12 for Format function to extract and standardize the information. The overall accuracy was 87.7%. For lymphovascular invasion, it was 98.2%. Developing and processing the prompts took 3.5 hours and 15 minutes, respectively. Utilizing the ChatGPT application programming interface cost US $65.8 and when factoring in the estimated wage, the total cost was US $95.4. In an estimated comparison, \"LLM-assisted manual\" and \"LLM\" methods were time- and cost-efficient compared to the \"full manual\" method.</p><p><strong>Conclusion: </strong>Developing and facilitating prompts for LLM to derive clinical factors was efficient to extract crucial information from huge medical records. This study demonstrated the potential of the application of natural language processing using LLM model in breast cancer patients. Prompts from the current study can be re-used for other research to collect clinical information.</p>","PeriodicalId":94184,"journal":{"name":"Radiation oncology journal","volume":"41 3","pages":"209-216"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7d/b6/roj-2023-00633.PMC10556835.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41159138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of sequential versus concurrent chemoradiation regimens in non-metastatic muscle-invasive bladder cancer.","authors":"Heidi M Vieira,&nbsp;David P Kasper,&nbsp;Runqiu Wang,&nbsp;Lynette M Smith,&nbsp;Charles A Enke,&nbsp;Raymond C Bergan,&nbsp;Benjamin A Teply,&nbsp;Michael J Baine","doi":"10.3857/roj.2023.00262","DOIUrl":"10.3857/roj.2023.00262","url":null,"abstract":"<p><strong>Purpose: </strong>The treatment approach for non-metastatic bladder cancer is guided by an invasion of the muscular layer of the bladder wall. Radical cystectomy is the recommended treatment for muscle-invasive disease. However, it has considerable morbidity and mortality and is not suited for many patients. Trimodality therapy consisting of chemoradiation after transurethral resection of bladder tumor offers a definitive approach with bladder-sparing potential. However, there is a lack of research defining the optimal combination of chemotherapy and radiation in this setting.</p><p><strong>Materials and methods: </strong>We extracted patient data from the National Cancer Database to compare survival outcomes and demographic factors in 2,227 non-metastatic bladder cancer patients who were treated with chemotherapy sequential to or concurrently with radiation. Sequential treatment was defined as chemotherapy beginning >14 days before radiation, and concurrent was defined as beginning within 14 days of the first radiation.</p><p><strong>Results: </strong>The sequential treatment group patients were younger (mean age, 74 vs. 78 years; p < 0.001) with more advanced disease. We found no difference in overall survival between patients who received chemotherapy sequential to radiation and those who received concurrent chemoradiation only (p = 0.533).</p><p><strong>Conclusion: </strong>Our data are concordant with a previous prospective study, and support that chemotherapy prior to radiation does not decrease survival outcomes relative to patients receiving only concurrent chemoradiation. Given that the sequential group had an overall higher stage but no difference in survival, downstaging chemotherapy prior to radiation may be helpful in these patients. Further studies including a larger, multi-institutional clinical trial are indicated to support clinical decision-making.</p>","PeriodicalId":94184,"journal":{"name":"Radiation oncology journal","volume":"41 3","pages":"154-162"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/13/90/roj-2023-00262.PMC10556844.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41161287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the past, present, and future of postoperative radiotherapy for N2 stage non-small cell lung cancer.","authors":"Byoung Hyuck Kim,&nbsp;Jae Sik Kim,&nbsp;Hak Jae Kim","doi":"10.3857/roj.2023.00430","DOIUrl":"10.3857/roj.2023.00430","url":null,"abstract":"<p><p>Despite conventionally applied postoperative radiotherapy (PORT) in pathological N2 (pN2) stage non-small cell lung cancer (NSCLC) considering high locoregional recurrence, its survival benefit has been a continuous topic of debate. Although several randomized clinical trials have been conducted, many of them have been withdrawn or analyzed without statistical significance due to slow accrual, making it difficult to determine the efficacy of PORT. Recently, the results of large-scale randomized clinical trials have been published, which showed some improvement in disease-free survival with PORT, but finally had no impact on overall survival. Based on these results, it was expected that the debate over PORT in pN2 patients with NSCLC would come to an end. However, since pN2 patients have different clinicopathologic features, it has become more important to carefully select the patient population who will benefit from PORT. In addition, given the development of systemic treatments such as molecular-targeted therapy and immunotherapy, it is crucial to evaluate whether there is any benefit to PORT in the midst of these recent changes. Therefore, determining the optimal treatment approach for NSCLC pN2 patients remains a complex issue that requires further research and evaluation.</p>","PeriodicalId":94184,"journal":{"name":"Radiation oncology journal","volume":"41 3","pages":"144-153"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f1/01/roj-2023-00430.PMC10556840.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41143834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of surface-guided radiation therapy in prostate cancer: comparative analysis of differences with skin marking-guided patient setup.","authors":"Jaeha Lee,&nbsp;Yeon Joo Kim,&nbsp;Youngmoon Goh,&nbsp;Eunyeong Yang,&nbsp;Ha Un Kim,&nbsp;Si Yeol Song,&nbsp;Young Seok Kim","doi":"10.3857/roj.2023.00521","DOIUrl":"10.3857/roj.2023.00521","url":null,"abstract":"<p><strong>Purpose: </strong>Surface-guided radiation therapy is an image-guided method using optical surface imaging that has recently been adopted for patient setup and motion monitoring during treatment. We aimed to determine whether the surface guide setup is accurate and efficient compared to the skin-marking guide in prostate cancer treatment.</p><p><strong>Materials and methods: </strong>The skin-marking setup was performed, and vertical, longitudinal, and lateral couch values (labeled as \"M\") were recorded. Subsequently, the surface-guided setup was conducted, and couch values (labeled as \"S\") were recorded. After performing cone-beam computed tomography (CBCT), the final couch values was recorded (labeled as \"C\"), and the shift value was calculated (labeled as \"Gap (M-S),\" \"Gap (M-C),\" \"Gap (S-C)\") and then compared. Additionally, the setup times for the skin marking and surface guides were also compared.</p><p><strong>Results: </strong>One hundred and twenty-five patients were analyzed, totaling 2,735 treatment fractions. Gap (M-S) showed minimal differences in the vertical, longitudinal, and lateral averages (-0.03 cm, 0.07 cm, and 0.06 cm, respectively). Gap (M-C) and Gap (S-C) exhibited a mean difference of 0.04 cm (p = 0.03) in the vertical direction, a mean difference of 0.35 cm (p = 0.52) in the longitudinal direction, and a mean difference of 0.11 cm (p = 0.91) in the lateral direction. There was no correlation between shift values and patient characteristics. The average setup time of the skin-marking guide was 6.72 minutes, and 7.53 minutes for the surface guide.</p><p><strong>Conclusion: </strong>There was no statistically significant difference between the surface and skin-marking guides regarding final CBCT shift values and no correlation between translational shift values and patient characteristics. We also observed minimal difference in setup time between the two methods. Therefore, the surface guide can be considered an accurate and time-efficient alternative to skin-marking guides.</p>","PeriodicalId":94184,"journal":{"name":"Radiation oncology journal","volume":"41 3","pages":"172-177"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f7/71/roj-2023-00521.PMC10556842.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41168278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}